Edward Pershing - 02 Dec 2024 Form 4 Insider Report for PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PVCT	Stock Options (Right to Buy)	Award	$0	+25,470,215		$0.000000	25,470,215	02 Dec 2024	Common Stock	25,470,215	$0.2862	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	The options vest in three equal annual installments beginning on December 2, 2024.